Lead candidate RMC-4630 has trials running in NSCLC and various solid tumors. Earlier, it published data from a phase 1 trial, a dose escalation study in combination with Cobimetinib in Relapsed/ ...
The FDA said it will grant some patients early access to Revolution Medicines' experimental pancreatic cancer drug ...
Erasca (ERAS), a potential rival to Revolution Medicines (RVMD) in developing drugs targeting cancer-causing mutations in the ...
Patients with one of the deadliest cancers have been pleading for an unapproved treatment that may prolong their lives.
TOS-358 is a covalent, pan-mutant, a-selective PI3K inhibitor designed to address key limitations of existing PI3Ka therapies which include limited mutation coverage and poor tolerability ...
"We welcome the Government's proactive approach in facilitating early access to medicines for critically ill patients and are delighted that pembrolizumab will be the first innovative medicine to be ...
The UK's Medicines and Healthcare Products Agency (MHRA) has announced that it will soon launch a new regulatory program intended to allow severely ill consumers earlier access to potentially ...
Preliminary clinical data presented at the InSiGHT Biennial Meeting demonstrate significant reductions in duodenal polyposis and the size of the co-existing desmoid tumor in a patient from the ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results